title: Treatments of AIDS-related Kaposi's sarcoma.
abstract: Although Kaposi's sarcoma (KS) has decreased in countries where the highly active antiretroviral therapy (HAART) regimen is available, however it remains, after non-Hodgkin's lymphomas, the most common malignancy in HIV+ patients. Advances in the treatment of AIDS-KS have been achieved, even though a gold standard therapy has not been yet defined. With the availability of HAART, a dramatic KS clinical response has been documented, making HAART essential in all patients. In case of aggressive and/or life threatening KS, more complex therapeutic schedules have to be taken into account, including chemotherapy and/or immunotherapy. Liposomal anthracyclines and paclitaxel have been approved by FDA as first line and second line mono-therapy, respectively. Interferon-alpha (INF-alpha) is the only immunomodulant agent to have shown a therapeutic effect. Among the new drugs, many antiangiogenetic agents have produced encouraging responses. Finally, the identification of the HHV-8 as a causative agent and new metalloproteinase inhibitors may offer promising targets for the KS treatment.
authors.affiliation: Oncology Division, Azienda Ospedaliera di Padova, Via Gattamelata 64, 35218 Padova, Italy. savina.aversa@sanita.padova.it
authors.forename: Savina Maria Lucia
authors.initials: SM
authors.lastname: Aversa
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Cattelan
authors.forename: Luigi
authors.initials: L
authors.lastname: Salvagno
authors.forename: Gino
authors.initials: G
authors.lastname: Crivellari
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Banna
authors.forename: Marco
authors.initials: M
authors.lastname: Trevenzoli
authors.forename: Vanna
authors.initials: V
authors.lastname: Chiarion-Sileni
authors.forename: Silvio
authors.initials: S
authors.lastname: Monfardini
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000465:Algorithms; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D019468:Disease Management; D006801:Humans; D012514:Sarcoma, Kaposi / Q000209:etiology / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D000998:Antiviral Agents